Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes

Microscopy Research and Technique

Volumn 50, Issue 3, 2000, Pages 229-235

  Raza, Azra ^a  

^a RUSH CANCER INSTITUTE   (United States)

Author keywords

Anti TNF therapies; Crohn's disease; Myelodysplastic syndromes; Rheumatoid arthritis

Indexed keywords

DISEASE CONTROL; DISEASES; MONOCLONAL ANTIBODIES;

ANTI-TNF THERAPY; CLINICAL EXPERIENCE; CLINICAL TRIAL; CROHN DISEASE; MYELODYSPLASTIC SYNDROMES; NEUTRALISATION; PROINFLAMMATORY CYTOKINES; RHEUMATOID ARTHRITIS; STATE OF THE ART; TNF Α;

T-CELLS;

AMIODARONE; CIPROFLOXACIN; DEXAMETHASONE; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 10; LENERCEPT; PENTOXIFYLLINE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ANTIBODY;

ARTICLE; CHRONIC DISEASE; CROHN DISEASE; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; HUMAN; INFLAMMATION; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SEPSIS; T LYMPHOCYTE;

EID: 0034254254     PISSN: 1059910X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0029(20000801)50:3<229::AID-JEMT6>3.0.CO;2-H     Document Type: Article

References (70)

1. Abraham EA. 1998. Cytokine modifiers: pipe dream or reality? Chest 113:2245-2275.
2. Abraham E, Wunderink R, et al. 1995. Efficacy and safety of monoclonal antibody to human TNF-α in patients with Sepsis syndrome: a randomized, controlled, double-blind, multi-center clinical trial. JAMA 273:934-941.
3. Beutler B, Krochin N, Milsark I, et al. 1986. Control of cachectin (TNF) synthesis: mechanism of endotoxin resistance. Science 232: 977-980.
4. Biorivant M, Marini M, Di Felice G, et al. 1999. Lamina propria T-cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis. Gastroenterology 116:557-565.
5. Blackwell TS, Christman JW. 1996. Sepsis and cytokines: current status. Br J Anesth 77:110-117.
6. Bondeson J, Foxwell BMJ, Brennan FM, Feldmann M. 1999. Defining therapeutic targets by using adenovirus: blocking NFKB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators. Proc Natl Acad Sci USA 96:5668-5673.
7. Breese E, McDonald TT. 1995. TNF-α secreting cells in normal and diseased human intestine. Adv Exp Med Biol 371 13:821-824.
8. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. 1989. Inhibitory effect of TNF-α antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 11:244.
9. Buchan G, Barrett K, Turner M, Chantry D, Maini RN, Feldmann M. 1988. Interleukin-1 and TNF mRNA expression in rheumatoid arthritis: prolonged production of IL1-b. Clin Exp Immunol 73:449-455.
10. Butler DM, Maini RN, Feldmann M, Brennan FM. 1995. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti-TNF-α antibody with the IL-1 receptor antagonist. Eur Cytokine Network 6:225-30.
11. Cannella B, Raine CS. 1991. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 37:424-435.
12. Cannon J, Toimpkins R, Gelfand J et al. 1990. Circulating IL-1 and TNF in septic shock and experimental endotoxin fever. J Infect Dis 161:79-84.
13. Chu CQ, Field M, Feldmann M, Maini RN. 1991. Localization of TNF-α in synovial tissue and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 34:1125.
14. Cohen J, Carlet J. 1996. INTERSEPT: an international, multi-center, placebo-controlled trial of monoclonal antibody to human TNF-α in patients with sepsis. Crit Care Med 24:1431-1440.
15. Dezube BJ, Lederman MM, Spritzler JG, Chapman B, Korvick JA, Flexner C, Dando S, Mattiacci MR, Ahlers CM, Zhang L et al.,. 1995. High-dose pentoxifylline in patients with AIDS: Inhibition of TNF production. National Institute of Allergy and Infectious Diseases AIDS clinical trial group. J Infect Dis 171:1628-1632.
16. Di Giovine FS, Nuki G, Duff GW. 1988. Tumor necrosis factor in synovial exudates. Ann Rheum Dis 47:768.
17. Dubost J-J, Soubrier M, Ristori J-M, Beaujon G, Qualid T, Bussiere J-L, Sauvezie B. 1997. An open study of the anti-TNF alpha agent pentoxifylline in the treatment of rheumatoid arthritis. Rev Rheum (Eng ed) 64:789-793.
18. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P et al. 1993. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to TNF-α. Arthritis Rheum 36:1681.
19. Feldmann M, Brennan FM, Maini RN. 1996. Role of cytokines in rheumatoid arthritis. Ann Rev Immunol 14:397-440.
20. Feldmann M, Taylor P, Paleolog E, Brennan FM, Maini RN. 1998. Anti-TNF-? therapy is useful in Rheumotoid arthritis and Crohn's disease: analysis of mechanism of action predicts utility in other diseases. Transpl Proc 30:4126-4127.
21. Feldmann M, Bondeson J, Brennan FM, Foxwell BMJ. 1999. The rationale for the current boom in anti-TNF-α treatment. Is there an effective means to define therapeutic targets for drugs that provide all the benefits of anti-TNF-α and minimize hazards. Ann Rheum Dis 58(Suppl 1):127-131.
22. Fiocchi C. The immune system in inflammatory bowel disease. 1997. Acta Gastroenterol Belg 6:156-162.
23. Fisher CJ Jr, Chainaut JF, Opal SM et al. 1994. Recombinant human IL1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double-blind, placebo-controlled trial. JAMA 271:1836-1843.
24. Hanauer SB. Safety of lufliximals in clinical trials. 1999. Aliment Phannacol Ther 13(Suppl 4):16-22.
25. Haworth B, Brennan FM, Chantry D, Turner M, Maini RN, Feldmann M. 1991. Expression of GM-CSF in rheumatoid arthritis: regulation by TNF-α. Eur J Immunol 21:2575.
26. Heaney ML, Golde DW. 1999. Myelodysplasia. N Engl J Med 340: 1649-1660.
27. Hinshaw LB, Tekamp-Olson P, Chang AC et al.,. 1990. Survival of primates in LDIUO septic shock following therapy with antibody to TNF-α. Civ Shock 30:279-292.
28. Hober D, Haque A, Wattre P, Beaucaire G, Mouton Y, Capron A. 1989. Production of tumor necrosis factor-alpha (TNF-α) and interleukin 1 (IL-1) in patients with AIDS. Enhanced level of TNF-α is related to higher cytotoxic activity. Clin Exp Immunol 78:329-333.
29. Ina K, Itoh J, Fukushima K et al. 1999. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a bcl-2/Bax mucosal imbalance. J Immunol 163:1081-1090.
30. Janssen JWG, Buschle M, Layton M, et al. 1989. Clonal analysis of MDS: Evidence of multipotent stem cell origin. Blood 73:248-254.
31. Klausner JD, Freedman VH, Kaplan G. 1996. Short analytic review. Thalidomide as an anti-TNF-α inhibitor: Implications for clinical use. Clin Immunol Immunopathol 81:219-223.
32. Koike M, Ishiyama T, Tomoyasu S, Tsuruoka N. 1995. Spontaneous cytokine overproduction by peripheral blood mononuclear cells from patients with myelodysplastic syndromes and aplastic anemia. Leuk Res 19:639-644.
33. List AF, Brasfield F, Heaten R et al. 1997. Stimulation of hematopoiesis by amifostine in patients with MDS. Blood 90:3364-3369.
34. Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ. 1997. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 99:699-705.
35. Mundle SD, Venugopal P, Pandav DV, Broady-Robinson L, Gezer S, Robin EL, Rifkin SR, Klein M, Alston DE, Hernandez BM, Rosi D, Alvi S, Shetty VT, Gregory SA, Raza A. 1996. Indication of an involvement of interleukin-1? Converting enzyme (ICE)-like protease in intramedullary apoptotic cell death in the bone marrows of patients with myelodysplastic syndromes (MDS). Blood 88:2640-2647.
36. Mundle S, Mativi BY, Cartlidge J, Dangerfield B, Zeitler D, Padhye A, Robinson L, Shetty V, Dar S, Broderick E, Venugopal P, Gregory SA, Raza A. 1999. Demonstration of CMV and EBV related mRNA transcripts in myelodysplasia. Blood 94:107a, abstr 470.
37. Perrault LP, Menasche P. 1999. Preconditioning: Can nature's shield be raised against surgical ischemic-reperfusion injury? Ann Thorac Surg 68:1988-1994.
38. Piguet PF, Gran GE, Vesin C, Loestcher H, Gentz R, Lesslauer W. 1992. Evolution of collagen arthritis in mice is arrested by treatment with anti-TNF antibody or a recombinant soluble TNF receptor. Immunology 77:510.
39. Porter SB. 1997. Current status of clinical trials with Anti-TNF. Chest 112:3395-3415.
40. Powrie FT. 1995. Cells in inflammatory bowel disease: protective and pathogenic roles. Immunity 3:171-174.
41. Prehal JT, Throckmorton DW, Carroll AJ III, et al. 1978. A common progenitor for human myeloid and lymphoid cells. Nature 274:540.
42. Prescent DH. 1999. Review article: the efficacy of infliximals in Crohn's disease: healing of fistuale. Aliment Pharmacol Ther 13(Suppl 4):23-28.
43. Pruneri G, Bertolini F, Soligo D et al. 1999. Angiogenesis in MDS. Br J Cancer 81:1398-1401.
44. Raza A. 1998a. Hypothesis: myelodysplastic syndromes may have a viral etiology. Int J Hematol 68:245-256.
45. Raza A. 1998b. The initial transforming event in myelodysplastic syndromes may be viral: the case for cytomegalovirus. Med Oncl 15:165-173.
46. Raza A. 2000. Consilence across evolving dysplasias affecting myeloid, cervical, esophageal, gastric and liver cells: common themes and emerging patterns. Leuk Res 24:63-72.
47. Raza A, Gezer S, Mundle S, Gao X-Z, Alvi S, Borok R, Rifkin S, Iftikhar A, Shetty V, Parcharidou A, Loew J, Marcus B, Khan Z, Chaney C, Showel J, Gregory S, Preisler H. 1995. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 86:268-276.
48. Raza A, Gregory SA, Preisler HD. 1996a. The myelodysplastic syndromes in 1996: Complex stem cell disorders counfounded by dual actions of cytokines. Leuk Res 20:881-890.
49. Raza A, Mundle S, Shetty V, Alvi S, Chopra H, Span L, Parcharidou A, Dar S, Venugopal P, Borok R, Gezer S, Showel J, Loew J, Robin E, Rifkin S, Alston D, Hernandez B, Shah R, Kaizer H, Gregory S. 1996b. A paradigm shift in myelodysplastic syndromes. Leukemia 10:1648-1652.
50. Raza A, Mundle S, Shetty V, Alvi S, Chopra H, Dar S, Venugopal P, Borok R, Gezer S, Showel J, Robin E, Rifkin S, Alston D, Hernandez B, Gregory S. 1996c. Novel insights into the biology of myelodysplastic syndromes: Excessive apoptosis and the role of cytokines. Int J Hematol 63:265-278.
51. Raza A, Alvi S, Broady-Robinson L, Showel M, Cartlifge J, Mundle SD, Shetty V, Borok RZ, Dar SE, Chopra HK, Span L, Parcharidou A, Hines C, Gezer S, Venugopal P, Loew J, Showel J, Alston D, Hernandez B, Rifkin S, Robin E, Shah R, Gregory S. 1997. Cell cycle kinetic studies in 68 patients with myelodysplatic syndromes following intravenous iodo-and/or bromodeoxyuridine. Exp Hematol 25:530-535.
52. Raza A, Venugopal P, Gezer S, Gregory S, Dong LM, Leurgens S, Mundle SD, Shetty VT, Alvi S, Ali A, Span L, Dar SE, Hines C, Hsu WT, Loew J, Borok RZ, Hernandez B, Robin E, Rifkin S, Alston D, Shah R, Preisler HD. 1998. Pilot study of pentoxifylline and Ciprofloxacin with or without dexamethasone produces encouraging results in myelodysplastic syndromes. In: Hiddemann W, Buchner T, Wormann B, Ritter J, Creutzig U, Keating M, Plunkett W, editors. Acute leukemias VII: experimental approaches and novel therapies. New York: Springer-Verlag, p 42-51.
53. Raza A, Dar S, Borok R, Lisak L, Andrews C, Ekbal M, Mazzoran L, Zorat F, Rifkin S, Robin E, Gregory S, Venugopal P. 1999b. Encouraging response to amifostine, pentoxifylline, ciprofloxacin, dexamethasone (A-PCD) + topotecan in patients with myelodysplastic syndromes (MDS). Blood 94:305a, abstr 365.
54. Raza A, Allampallam K, Shetty V, Mundle S, Borok R, Lisak L, Andrews C, Ekbal M, Mazzoran L, Zorat F, Henderson B, Dangerfield B, Ansaarie I, Hussaini S, Broady-Robinson L, Venugopal P. 1999c. Biologic and clinical response to recombinant human soluble tumor necrosis factor receptor (Enbrel) in patients with myelodysplastic syndromes (MDS). Blood 94:171b, abstr 3941.
55. Raza A, Lisak L, Andrews C, Little L, Muzammil M, Alvi S, Mazzoran L, Zorat F, Akber A, Ekbal M, Razvi S, Venugopal P. 1999d. Thalidomide produces transfusion independence in patients with longstanding refractory anemias and myelodysplastic syndromes (MDS). Blood 94:661a, abstr 2935.
56. Raza A, Qawi H, Lisak I, Andric T, Dar S, Andrews C, Venugopal P, Gezer S, Gregory S, Loew J, Robin E, Rifkin S, Hsu W-T, Huang R-W. 2000. Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxyfylline, and ciprofloxacin with or without dexamethasone. Blood 95:1580-1587.
57. Reza S, Shetty V, Dar S, Qawi H, Raza A. 1998. Tumor necrosis factor alpha levels decrease with anti-cytokine therapy in patients with myelodysplastic syndromes. J Interferon Cytokine Res 18:871-877.
58. Rutgeerts P, Paert F. 1999. New strategies in the manaement of inflammatory bowel disease. Acta Clin Belg 54:274-280.
59. Selmaj K et al. 1991. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest 87:949-954.
60. Shetty V, Mundle S, Alvi S, Showel M, Broady-Robinson L, Dar S, Borok R, Showel J, Gregory S, Rifkin S, Gezer S, parcharidou A, Venugopal P, Shah R, Hernandez B, Klein M, Alston D, Robin E, Dominquez C, Raza A. 1996. Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leuk Res 20:891-900.
61. Stack WA, Mann SD, Roy AJ, et al. 1997. Randomised controlled trial of CDP57/antibody to TNF-α in Crohn's disease. Lancet 349:521-524.
62. Targan SR, Hanauer SB, van Deventer SJ, et al. 1997. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's disease cA2 Study Group. New Engl J Med 337:1029-1035.
63. Teramura M, Mizoguchi H. 1996. Special education: aplastic anemia. Oncologist 1:187-189.
64. Thorbecke GJ, Shah R, Leu CH, Kuruvilla AP, Hardison AM, Palladino MA. 1992. Involvement of endogenous TNF-α and TGF-β during induction of collagen type II arthritis in mice. Proc Natl Acad Sci USA 89:7375.
65. Tracey K, Cerami A. 1993. TNF-α: an updated review of its biology. Crit Care Med 21(Suppl 10):5415-5422.
66. Van Deventer SJ. 1997. TNF-α and Crohn's disease. Gut 40:443-448.
67. Van Dullermen HM, van Deventer SJH, Homme DW et al.. 1995. Treatment of Crohn's disease with anti-TNF chimeric monoclonal antibody cA2. Gastroenterology 109:129-135
68. Wang C-Y, Mayo MW, Baldwin AS. 1996. TNF and cancer therapy-induced apoptosis: potentiation by inhibition of NFKB. Science 274:778-787.
69. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ. 1999. A trial of etanercept, a recombinant TNF receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving metrotrexate. N Eng J Med 28; 340:253-259.
70. Williams L, Gibbons DL, Gearing A, Feldmann M, Brennan FM. 1996. Paradoxical effects of a synthetic metalloproteinase inhibitor which blocks both p55 and p75 TNF receptor shedding and TNF-α processing. J Clin Invest 97:2833.